Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

The OMERACT Emerging Leaders Program: The Good, the Bad and the Future.

Flurey CA, Tugwell PS, Black RJ, Halls S, Page MJ, Robson JC, Sahbudin I, Siddle HJ, Sinnathurai P, Stok KS, Richards B.

J Rheumatol. 2019 Mar 1. pii: jrheum.181126. doi: 10.3899/jrheum.181126. [Epub ahead of print]

PMID:
30824659
2.

OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions.

Toupin-April K, Barton JL, Fraenkel L, Meara A, Li LC, Brooks P, de Wit M, Stacey D, Légaré F, Shea B, Lyddiatt A, Hofstetter C, Christensen R, Scholte Voshaar M, Suarez-Almazor ME, Boonen A, Meade T, March L, Jull JE, Campbell W, Alten R, Karuranga S, Morgan EM, Kelly A, Kaufman J, Hill S, Maxwell LJ, Beaton D, El-Miedany Y, Mittoo S, Bartlett SJ, Singh JA, Tugwell PS.

J Rheumatol. 2019 Feb 1. pii: jrheum.181071. doi: 10.3899/jrheum.181071. [Epub ahead of print]

PMID:
30709963
3.

OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis.

Robson JC, Tomasson G, Milman N, Ashdown S, Boonen A, Casey GC, Cronholm PF, Cuthbertson D, Dawson J, Direskeneli H, Easley E, Kermani TA, Farrar JT, Gebhart D, Lanier G, Luqmani RA, Mahr A, McAlear CA, Peck J, Shea B, Shea JA, Sreih AG, Tugwell PS, Merkel PA.

J Rheumatol. 2017 Oct;44(10):1529-1535. doi: 10.3899/jrheum.161139. Epub 2017 Sep 1.

4.

Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting.

Toupin-April K, Barton J, Fraenkel L, Li LC, Brooks P, De Wit M, Stacey D, Légaré F, Meara A, Shea B, Lyddiatt A, Hofstetter C, Gossec L, Christensen R, Scholte-Voshaar M, Suarez-Almazor ME, Boonen A, Meade T, March L, Pohl C, Jull JE, Sivarajah S, Campbell W, Alten R, Karuranga S, Morgan E, Kaufman J, Hill S, Maxwell LJ, Welch V, Beaton D, El-Miedany Y, Tugwell PS.

J Rheumatol. 2017 Oct;44(10):1544-1550. doi: 10.3899/jrheum.161241. Epub 2017 Aug 1.

5.

An OMERACT Initiative Toward Consensus to Identify and Characterize Candidate Contextual Factors: Report from the Contextual Factors Working Group.

Finger ME, Boonen A, Woodworth TG, Escorpizo R, Christensen R, Nielsen SM, Leong AL, Scholte Voshaar M, Flurey CA, Milman N, Verstappen SM, Alten R, Guillemin F, Kloppenburg M, Beaton DE, Tugwell PS, March LM, Furst DE, Pohl C.

J Rheumatol. 2017 Nov;44(11):1734-1739. doi: 10.3899/jrheum.161200. Epub 2017 May 1.

PMID:
28461648
6.

Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest Group.

Petkovic J, Barton JL, Flurey C, Goel N, Bartels CM, Barnabe C, de Wit MPT, Lyddiatt A, Lacaille D, Welch V, Boonen A, Shea B, Christensen R, Maxwell LJ, Campbell W, Jull J, Toupin-April K, Singh JA, Goldsmith CH, Sreih AG, Pohl C, Hofstetter C, Beaton DE, Buchbinder R, Guillemin F, Tugwell PS.

J Rheumatol. 2017 Nov;44(11):1727-1733. doi: 10.3899/jrheum.160975. Epub 2017 Feb 15.

7.

Ms. A.M. Taylor, et al reply.

Taylor AM, Taylor JO, Singh JA, Conaghan PG, Choy EH, Tugwell PS, Kaiser U, Strand V, Simon LS, Mease PJ.

J Rheumatol. 2016 Apr;43(4):826. doi: 10.3899/jrheum.151456. No abstract available.

8.

Do "Evidence-Based Recommendations" Need to Reveal the Evidence? Minimal Criteria Supporting an "Evidence Claim".

Christensen R, Singh JA, Wells GA, Tugwell PS.

J Rheumatol. 2015 Oct;42(10):1737-9. doi: 10.3899/jrheum.150846. No abstract available.

PMID:
26429204
9.

A Call for Evidence-based Decision Making When Selecting Outcome Measurement Instruments for Summary of Findings Tables in Systematic Reviews: Results from an OMERACT Working Group.

Beaton DE, Terwee CB, Singh JA, Hawker GA, Patrick DL, Burke LB, Toupin-April K, Tugwell PS.

J Rheumatol. 2015 Oct;42(10):1954-1961. doi: 10.3899/jrheum.141446. Epub 2015 Sep 15.

PMID:
26373567
10.

Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Using the OMERACT Process.

Robson JC, Milman N, Tomasson G, Dawson J, Cronholm PF, Kellom K, Shea J, Ashdown S, Boers M, Boonen A, Casey GC, Farrar JT, Gebhart D, Krischer J, Lanier G, McAlear CA, Peck J, Sreih AG, Tugwell PS, Luqmani RA, Merkel PA.

J Rheumatol. 2015 Nov;42(11):2204-9. doi: 10.3899/jrheum.141143. Epub 2015 Sep 1. Review.

11.

OMERACT Filter Evidence Supporting the Measurement of At-work Productivity Loss as an Outcome Measure in Rheumatology Research.

Beaton DE, Dyer S, Boonen A, Verstappen SM, Escorpizo R, Lacaille DV, Bosworth A, Gignac MA, Leong A, Purcaru O, Leggett S, Hofstetter C, Peterson IF, Tang K, Fautrel B, Bombardier C, Tugwell PS.

J Rheumatol. 2016 Jan;43(1):214-22. doi: 10.3899/jrheum.141077. Epub 2015 Sep 1. Review.

PMID:
26329339
12.

The Spirit of OMERACT: Q Methodology Analysis of Conference Characteristics Valued by Delegates.

Flurey CA, Kirwan JR, Hadridge P, Richards P, Grosskleg S, Tugwell PS.

J Rheumatol. 2015 Oct;42(10):1982-1992. doi: 10.3899/jrheum.150113. Epub 2015 Aug 15.

PMID:
26276970
13.

Harmonizing Pain Outcome Measures: Results of the Pre-OMERACT Meeting on Partnerships for Consensus on Patient-important Pain Outcome Domains Between the Cochrane Musculoskeletal Group and OMERACT.

Phillips K, Taylor A, Mease PJ, Simon LS, Conaghan PG, Choy EH, Singh JA, Strand V, Gossec L, Kaiser U, de Wit M, Ostelo R, Maxwell L, Tugwell PS.

J Rheumatol. 2015 Oct;42(10):1943-1946. doi: 10.3899/jrheum.141386. Epub 2015 Aug 1.

PMID:
26233508
14.

Is Chronic Pain a Disease in Its Own Right? Discussions from a Pre-OMERACT 2014 Workshop on Chronic Pain.

Taylor AM, Phillips K, Taylor JO, Singh JA, Conaghan PG, Choy EH, Tugwell PS, Kaiser U, Strand V, Simon LS, Mease PJ.

J Rheumatol. 2015 Oct;42(10):1947-1953. doi: 10.3899/jrheum.141328. Epub 2015 Jul 1.

PMID:
26136483
15.

Toward Ensuring Health Equity: Readability and Cultural Equivalence of OMERACT Patient-reported Outcome Measures.

Petkovic J, Epstein J, Buchbinder R, Welch V, Rader T, Lyddiatt A, Clerehan R, Christensen R, Boonen A, Goel N, Maxwell LJ, Toupin-April K, De Wit M, Barton J, Flurey C, Jull J, Barnabe C, Sreih AG, Campbell W, Pohl C, Duruöz MT, Singh JA, Tugwell PS, Guillemin F.

J Rheumatol. 2015 Dec;42(12):2448-59. doi: 10.3899/jrheum.141168. Epub 2015 Jun 15. Review.

16.

Development of a Draft Core Set of Domains for Measuring Shared Decision Making in Osteoarthritis: An OMERACT Working Group on Shared Decision Making.

Toupin-April K, Barton J, Fraenkel L, Li L, Grandpierre V, Guillemin F, Rader T, Stacey D, Légaré F, Jull J, Petkovic J, Scholte-Voshaar M, Welch V, Lyddiatt A, Hofstetter C, De Wit M, March L, Meade T, Christensen R, Gaujoux-Viala C, Suarez-Almazor ME, Boonen A, Pohl C, Martin R, Tugwell PS.

J Rheumatol. 2015 Dec;42(12):2442-7. doi: 10.3899/jrheum.141205. Epub 2015 Apr 15. Review.

17.

Dialogue on Developing Consensus on Measurement and Presentation of Patient-important Outcomes, Using Pain Outcomes as an Exemplar, in Systematic Reviews: A Preconference Meeting at OMERACT 12.

Tugwell PS, Maxwell LJ, Beaton DE, Busse JW, Christensen R, Conaghan PG, Simon LS, Terwee C, Tovey D, Wells GA, Williamson P.

J Rheumatol. 2015 Oct;42(10):1931-1933. doi: 10.3899/jrheum.141430. Epub 2015 Feb 1.

PMID:
25641896
18.

Worker productivity outcome measures: OMERACT filter evidence and agenda for future research.

Tang K, Boonen A, Verstappen SM, Escorpizo R, Luime JJ, Lacaille D, Fautrel B, Bosworth A, Cifaldi M, Gignac MA, Hofstetter C, Leong A, Montie P, Petersson IF, Purcaru O, Bombardier C, Tugwell PS, Beaton DE.

J Rheumatol. 2014 Jan;41(1):165-76. doi: 10.3899/jrheum.130815. Epub 2013 Oct 15.

PMID:
24128774
19.

Translation and validation of the Dutch version of the Effective Consumer Scale (EC-17).

ten Klooster PM, Taal E, Siemons L, Oostveen JC, Harmsen EJ, Tugwell PS, Rader T, Lyddiatt A, van de Laar MA.

Qual Life Res. 2013 Mar;22(2):423-9. doi: 10.1007/s11136-012-0162-2. Epub 2012 Mar 28.

20.

Influencing health equity: role of the effective consumer scale in measuring skills and abilities in a middle income country.

Rader T, Ueffing E, Garcia-Elorrio E, Idzerda L, Ciapponi A, Irazola V, Welch V, Lyddiatt A, Shea B, Newman S, Osborne R, Tugwell PS.

J Rheumatol. 2011 Aug;38(8):1798-802. doi: 10.3899/jrheum.110407.

PMID:
21807803
21.

Health literacy: what is it and why is it important to measure?

Buchbinder R, Batterham R, Ciciriello S, Newman S, Horgan B, Ueffing E, Rader T, Tugwell PS, Osborne RH.

J Rheumatol. 2011 Aug;38(8):1791-7. doi: 10.3899/jrheum.110406.

PMID:
21807802
22.

Measuring the impact of arthritis on worker productivity: perspectives, methodologic issues, and contextual factors.

Tang K, Escorpizo R, Beaton DE, Bombardier C, Lacaille D, Zhang W, Anis AH, Boonen A, Verstappen SM, Buchbinder R, Osborne RH, Fautrel B, Gignac MA, Tugwell PS.

J Rheumatol. 2011 Aug;38(8):1776-90. doi: 10.3899/jrheum.110405.

PMID:
21807801
23.

Valuing health for clinical and economic decisions: directions relevant for rheumatologists.

Harrison MJ, Bansback NJ, Marra CA, Drummond M, Tugwell PS, Boonen A.

J Rheumatol. 2011 Aug;38(8):1770-5. doi: 10.3899/jrheum.110404.

PMID:
21807800
24.

It's good to feel better but it's better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10.

Strand V, Boers M, Idzerda L, Kirwan JR, Kvien TK, Tugwell PS, Dougados M.

J Rheumatol. 2011 Aug;38(8):1720-7. doi: 10.3899/jrheum.110392.

PMID:
21807792
25.

Domains selection for patient-reported outcomes: current activities and options for future methods.

Tugwell PS, Petersson IF, Boers M, Gossec L, Kirwan JR, Rader T, Sanderson TC, van de Laar MA, Ueffing E, Witter JP.

J Rheumatol. 2011 Aug;38(8):1702-10. doi: 10.3899/jrheum.110389.

PMID:
21807789
26.

Overview of the patient perspective at OMERACT 10--conceptualizing methods for developing patient-reported outcomes.

Kirwan JR, Tugwell PS.

J Rheumatol. 2011 Aug;38(8):1699-701. doi: 10.3899/jrheum.110388.

PMID:
21807788
27.

Tuberculosis surveillance in Cape Town, South Africa: an evaluation.

Heidebrecht CL, Tugwell PS, Wells GA, Engel ME.

Int J Tuberc Lung Dis. 2011 Jul;15(7):912-8. doi: 10.5588/ijtld.10.0296.

PMID:
21682964
28.

Presenting evidence to patients online: what do web users think of consumer summaries of cochrane musculoskeletal reviews?

Brehaut JC, Santesso N, O'Connor AM, Lott A, Lindgaard G, Syrowatka A, Graham ID, Tugwell PS.

J Med Internet Res. 2011 Jan 18;13(1):e5. doi: 10.2196/jmir.1532.

29.

Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).

Khanna D, Distler O, Avouac J, Behrens F, Clements PJ, Denton C, Foeldvari I, Giannini E, Huscher D, Kowal-Bielecka O, Lovell D, Matucci-Cerinic M, Mayes M, Merkel PA, Nash P, Opitz CF, Pittrow D, Rubin L, Seibold JR, Steen V, Strand CV, Tugwell PS, Varga J, Zink A, Furst DE; CRISS; EPOSS.

J Rheumatol. 2009 Oct;36(10):2356-61. doi: 10.3899/jrheum.090372.

30.

How to ascertain drug safety in the context of benefit. Controversies and concerns.

Simon LS, Strand CV, Boers M, Brooks PM, Tugwell PS, Bombardier C, Fries JF, Henry D, Goldkind L, Guyatt G, Laupacis A, Lynd L, Macdonald T, Mamdani M, Moore A, Saag KG, Silman AJ, Stevens R, Tyndall A.

J Rheumatol. 2009 Sep;36(9):2114-21. doi: 10.3899/jrheum.090591. Erratum in: J Rheumatol. 2010 Mar;37(3):681. Saag, Ken S [corrected to Saag, Kenneth G].

PMID:
19738223
31.

Observations from the OMERACT Drug Safety Summit, May 2008.

Simon LS, Strand CV, Boers M, Brooks PM, Henry D, Tugwell PS.

J Rheumatol. 2009 Sep;36(9):2110-3. doi: 10.3899/jrheum.090590.

PMID:
19738222
32.

Measuring worker productivity: frameworks and measures.

Beaton D, Bombardier C, Escorpizo R, Zhang W, Lacaille D, Boonen A, Osborne RH, Anis AH, Strand CV, Tugwell PS.

J Rheumatol. 2009 Sep;36(9):2100-9. doi: 10.3899/jrheum.090366. Review.

PMID:
19738221
33.

Responsiveness of the Effective Consumer Scale (EC-17).

Santesso N, Rader T, Wells GA, O'Connor AM, Brooks PM, Driedger M, Gallois C, Kristjansson E, Lyddiatt A, O'Leary G, Prince M, Stacey D, Wale J, Welch V, Wilson AJ, Tugwell PS.

J Rheumatol. 2009 Sep;36(9):2087-91. doi: 10.3899/jrheum.090363.

PMID:
19738218
34.

Assessing quality of sleep in patients with rheumatoid arthritis.

Wells GA, Li T, Kirwan JR, Peterson J, Aletaha D, Boers M, Bresnihan B, Dougados M, Idzerda L, Nicklin J, Suarez-Almazor M, Welch V, Tugwell PS.

J Rheumatol. 2009 Sep;36(9):2077-86. doi: 10.3899/jrheum.090362. Review.

PMID:
19738217
35.

Progress on incorporating the patient perspective in outcome assessment in rheumatology and the emergence of life impact measures at OMERACT 9.

Kirwan JR, Newman S, Tugwell PS, Wells GA, Hewlett S, Idzera L, Laslo B, March LM, Minnock P, Montie P, Nicklin J, Rader T, Richards P, Sanderson TC, Suarez-Almazor M, Tanjong-Ghogomu E, Ueffing E, Welch V.

J Rheumatol. 2009 Sep;36(9):2071-6. doi: 10.3899/jrheum.090360.

PMID:
19738216
36.

Patient perspective on outcomes in rheumatology -- a position paper for OMERACT 9.

Kirwan JR, Newman S, Tugwell PS, Wells GA.

J Rheumatol. 2009 Sep;36(9):2067-70. doi: 10.3899/jrheum.090359.

PMID:
19738215
37.

The OMERACT Initiative. Towards a reference approach to derive QALY for economic evaluations in rheumatology.

Boonen A, Maetzel A, Drummond M, Suarez-Almazor M, Harrison M, Welch V, Tugwell PS.

J Rheumatol. 2009 Sep;36(9):2045-9. doi: 10.3899/jrheum.090355.

PMID:
19738211
38.

Investigating the validity of the minimal disease activity state for patients with rheumatoid arthritis treated with abatacept.

Wells GA, Boers M, Li T, Tugwell PS.

J Rheumatol. 2009 Feb;36(2):260-5. doi: 10.3899/jrheum.080059. Epub 2009 Jan 22.

PMID:
19208559
39.

Knowledge translation for effective consumers.

Tugwell PS, Santesso NA, O'Connor AM, Wilson AJ; Effective Consumer Investigative Group.

Phys Ther. 2007 Dec;87(12):1728-38. Epub 2007 Sep 25. Review.

PMID:
17906288
40.

Development of the effective musculoskeletal consumer scale.

Kristjansson E, Tugwell PS, Wilson AJ, Brooks PM, Driedger SM, Gallois C, O'Connor AM, Qualman A, Santesso N, Wale J, Wells GA.

J Rheumatol. 2007 Jun;34(6):1392-400.

PMID:
17552066
41.

Systematic reviews from the Cochrane Musculoskeletal Group.

Santesso N, Maxwell L, Tugwell PS, Buchbinder R, Johnston R; Editorial Board of Cochrane Musculoskeletal Group.

J Can Chiropr Assoc. 2006 Dec;50(4):238-43. No abstract available.

42.

Knowledge transfer to clinicians and consumers by the Cochrane Musculoskeletal Group.

Santesso N, Maxwell L, Tugwell PS, Wells GA, O'connor AM, Judd M, Buchbinder R.

J Rheumatol. 2006 Nov;33(11):2312-8.

PMID:
17086612
43.

Method guidelines for Cochrane Musculoskeletal Group systematic reviews.

Maxwell L, Santesso N, Tugwell PS, Wells GA, Judd M, Buchbinder R.

J Rheumatol. 2006 Nov;33(11):2304-11.

PMID:
17086611
44.

Prospective evaluation of preferences and quality of life in women with hip fractures.

Cranney AB, Coyle D, Hopman WM, Hum V, Power B, Tugwell PS.

J Rheumatol. 2005 Dec;32(12):2393-9.

PMID:
16331770
45.

Scope for improvement in the quality of reporting of systematic reviews. From the Cochrane Musculoskeletal Group.

Shea B, Bouter LM, Grimshaw JM, Francis D, Ortiz Z, Wells GA, Tugwell PS, Boers M.

J Rheumatol. 2006 Jan;33(1):9-15. Epub 2005 Nov 1.

PMID:
16267878
46.

Attributes and skills of an effective musculoskeletal consumer.

Tugwell PS, Wilson AJ, Brooks PM, Driedger SM, Gallois C, O'Connor AM, Qualman A, Santesso N, Wale J, Wells GA.

J Rheumatol. 2005 Nov;32(11):2257-61.

PMID:
16265713
47.

Standardized assessment of adverse events in rheumatology clinical trials: summary of the OMERACT 7 drug safety module update.

Lassere MN, Johnson KR, Boers M, Carlton K, Day RO, de Wit M, Edwards IR, Fries JF, Furst DE, Kirwan JR, Tugwell PS, Woodworth TG, Brooks PM.

J Rheumatol. 2005 Oct;32(10):2037-41.

PMID:
16206366
48.

Challenges and progress in adverse event ascertainment and reporting in clinical trials.

Lassere MN, Johnson KR, Woodworth TG, Furst DE, Fries JF, Kirwan JR, Tugwell PS, Day RO, Brooks PM.

J Rheumatol. 2005 Oct;32(10):2030-2. Review.

PMID:
16206364
49.

Minimal disease activity for rheumatoid arthritis: a preliminary definition.

Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, Aletaha D, Anderson JJ, Bombardier C, Dougados M, Emery P, Felson DT, Fransen J, Furst DE, Hazes JM, Johnson KR, Kirwan JR, Landewé RB, Lassere MN, Michaud K, Suarez-Almazor M, Silman AJ, Smolen JS, Van der Heijde DM, van Riel PL, Wolfe F, Tugwell PS.

J Rheumatol. 2005 Oct;32(10):2016-24.

PMID:
16206362

Supplemental Content

Loading ...
Support Center